These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 9149744)

  • 1. Sensorimotor neurotoxicity associated with high-dose deferoxamine treatment.
    Levine JE; Cohen A; MacQueen M; Martin M; Giardina PJ
    J Pediatr Hematol Oncol; 1997; 19(2):139-41. PubMed ID: 9149744
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Abnormal fundus autofluorescence results of patients in long-term treatment with deferoxamine.
    Viola F; Barteselli G; Dell'arti L; Vezzola D; Villani E; Mapelli C; Zanaboni L; Cappellini MD; Ratiglia R
    Ophthalmology; 2012 Aug; 119(8):1693-700. PubMed ID: 22480740
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ototoxicity in hemoglobinopathy patients chelated with desferrioxamine.
    Styles LA; Vichinsky EP
    J Pediatr Hematol Oncol; 1996 Feb; 18(1):42-5. PubMed ID: 8556369
    [TBL] [Abstract][Full Text] [Related]  

  • 4. High-dose intravenous desferrioxamine (DFO) delivery in four thalassemic patients allergic to subcutaneous DFO administration.
    Lombardo T; Ferro G; Frontini V; Percolla S
    Am J Hematol; 1996 Jan; 51(1):90-2. PubMed ID: 8571945
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Successful desensitization of a case with desferrioxamine hypersensitivity.
    Gülen F; Demir E; Tanaç R; Aydinok Y; Gulen H; Yenigün A; Can D
    Minerva Pediatr; 2006 Dec; 58(6):571-4. PubMed ID: 17093379
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prospective evaluation of patient-reported outcomes during treatment with deferasirox or deferoxamine for iron overload in patients with beta-thalassemia.
    Cappellini MD; Bejaoui M; Agaoglu L; Porter J; Coates T; Jeng M; Lai ME; Mangiagli A; Strauss G; Girot R; Watman N; Ferster A; Loggetto S; Abish S; Cario H; Zoumbos N; Vichinsky E; Opitz H; Ressayre-Djaffer C; Abetz L; Rofail D; Baladi JF
    Clin Ther; 2007 May; 29(5):909-917. PubMed ID: 17697909
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Use of deferoxamine (DFO) in transfusion-dependent β-thalassemia during pregnancy: A retrospective study.
    Piccioni MG; Capone C; Vena F; Del Negro V; Schiavi MC; D'Ambrosio V; Giancotti A; Smacchia MP; Brunelli R
    Taiwan J Obstet Gynecol; 2020 Jan; 59(1):120-122. PubMed ID: 32039778
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pattern of iron chelation therapy in Egyptian beta thalassemic patients: Mansoura University Children's Hospital experience.
    Abdelrazik N
    Hematology; 2007 Dec; 12(6):577-85. PubMed ID: 17852442
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Intravenous chelation therapy during transplantation for thalassemia.
    Gaziev D; Giardini C; Angelucci E; Polchi P; Galimberti M; Baronciani D; Erer B; Maiello A; Lucarelli G
    Haematologica; 1995; 80(4):300-4. PubMed ID: 7590497
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Deferoxamine-related ocular toxicity: incidence and outcome in a pediatric population.
    Baath JS; Lam WC; Kirby M; Chun A
    Retina; 2008 Jun; 28(6):894-9. PubMed ID: 18536609
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sensorineural hearing loss in children with thalassemia major in Northern Greece.
    Kontzoglou G; Koussi A; Tsatra J; Noussios G; Vital V; Sagarakis G; Athanassiou M
    Int J Pediatr Otorhinolaryngol; 1996 May; 35(3):223-30. PubMed ID: 8762595
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A practical chelation protocol based on stratification of thalassemic patients by serum ferritin and magnetic resonance imaging cardiac T2*.
    Ha SY; Mok AS; Chu WC; Raskalkar DD; Cheuk DK; Chiang AK; Ho MH; Chan GC
    Hemoglobin; 2009; 33(5):323-31. PubMed ID: 19814678
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Combination therapy of deferasirox and deferoxamine shows significant improvements in markers of iron overload in a patient with β-thalassemia major and severe iron burden.
    Voskaridou E; Komninaka V; Karavas A; Terpos E; Akianidis V; Christoulas D
    Transfusion; 2014 Mar; 54(3):646-9. PubMed ID: 23834310
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Combination of deferasirox and deferoxamine in clinical practice: an alternative scheme of chelation in thalassemia major patients.
    Cassinerio E; Orofino N; Roghi A; Duca L; Poggiali E; Fraquelli M; Zanaboni L; Cappellini MD
    Blood Cells Mol Dis; 2014 Sep; 53(3):164-7. PubMed ID: 24846580
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Increased survival and reversion of iron-induced cardiac disease in patients with thalassemia major receiving intensive combined chelation therapy as compared to desferoxamine alone.
    Lai ME; Grady RW; Vacquer S; Pepe A; Carta MP; Bina P; Sau F; Cianciulli P; Maggio A; Galanello R; Farci P
    Blood Cells Mol Dis; 2010 Aug; 45(2):136-9. PubMed ID: 20678715
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Toxic effects of high-dose deferoxamine treatment in patients with iron overload: an electrophysiological study of cerebral and visual function.
    Marciani MG; Cianciulli P; Stefani N; Stefanini F; Peroni L; Sabbadini M; Maschio M; Trua G; Papa G
    Haematologica; 1991; 76(2):131-4. PubMed ID: 1937171
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Socio-psychological impact of infused iron chelation therapy with deferoxamine in metropolitan France: ISOSFER study results.
    Thuret I; Hacini M; Pégourié-Bandelier B; Gardembas-Pain M; Bisot-Locard S; Merlat-Guitard A; Bachir D
    Hematology; 2009 Dec; 14(6):315-22. PubMed ID: 19941737
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Deferoxamine-induced platyspondyly in hypertransfused thalassemic patients.
    Levin TL; Sheth S; Berdon WE; Ruzal-Shapiro C; Piomelli S
    Pediatr Radiol; 1995 Nov; 25 Suppl 1():S122-4. PubMed ID: 8577502
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Serum ferritin level as a predictor of impaired growth and puberty in thalassemia major patients.
    Shalitin S; Carmi D; Weintrob N; Phillip M; Miskin H; Kornreich L; Zilber R; Yaniv I; Tamary H
    Eur J Haematol; 2005 Feb; 74(2):93-100. PubMed ID: 15654898
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Compliance and satisfaction with deferasirox (Exjade®) compared with deferoxamine in patients with transfusion-dependent beta-thalassemia.
    Haghpanah S; Zarei T; Zahedi Z; Karimi M
    Hematology; 2014 Jun; 19(4):187-91. PubMed ID: 24074344
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.